Journal Mobile Options
Table of Contents
Vol. 27, No. 4, 2006
Issue release date: May 2006
Tumor Biol 2006;27:187–194

Elevated Serum Soluble CD30 Precedes the Development of AIDS-Associated Non-Hodgkin’s B Cell Lymphoma

Breen E.C. · Fatahi S. · Epeldegui M. · Boscardin W.J. · Detels R. · Martínez-Maza O.
Departments of aObstetrics and Gynecology and bMicrobiology, Immunology, and Molecular Genetics, David Geffen School of Medicine and Departments of cBiostatistics and dEpidemiology, School of Public Health, University of California, Los Angeles, Calif., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


CD30, first described as the Ki antigen on malignant B cells in Hodgkin’s lymphoma, is also expressed on normal activated B and T cells. It can be cleaved from the cell surface and detected in normal serum as soluble CD30 (sCD30), where it can be an indicator of levels of immune activation. In a cross-sectional study utilizing archived sera at a time point close to but preceding a diagnosis of acquired immunodeficiency syndrome (AIDS)-associated non-Hodgkin’s B cell lymphoma, AIDS lymphoma subjects (n = 49) showed elevated mean levels of sCD30 compared to controls with AIDS but no malignancy (n = 44, p < 0.01), HIV-infected but relatively healthy (n = 47, p < 0.001), or HIV-seronegative controls (n = 44, p < 0.001). Serum sCD30 was significantly correlated to serum levels of the B cell cytokines interleukin-6 (IL-6), IL-10, and sCD23, but only among lymphoma subjects (p ≤ 0.05). Correlations between sCD30 and other markers of immune system activation were seen among all HIV-infected subjects (sCD27, sCD44, CXCL13, p < 0.05). These observations suggest that sCD30, especially in combination with other immune system molecules, could be an important biomarker for an immune system environment conducive to B cell hyperactivation and the development of AIDS-associated B cell lymphoma.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Knowles DM: Immunophenotypic markers useful in the diagnosis and classification of hematopoietic neoplasms; in Knowles DM (ed): Neoplastic Hematopathology. Philadelphia, Lippincott Williams & Wilkins, 2001, pp 93–226.
  2. Croft M: Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol 2003;3:609–620.
  3. Younes A, Aggarwall BB: Clinical implications of the tumor necrosis factor family in benign and malignant hematologic disorders. Cancer 2003;98:458–467.
  4. Nadali G, Vinante F, Stein H, Todeschini G, Tecchio C, Morosato L, Chilosi M, Menestrina F, Kinney MC, Greer JP, Latza U, Perona G, Pizzolo G: Serum levels of the soluble form of CD30 molecule as a tumor marker in CD30+ anaplastic large-cell lymphoma. J Clin Oncol 1995;13:1355–1360.
  5. Zinzani PL, Pileri S, Bendandi M, Buzzi M, Sabattini E, Ascani S, Gherlinzoni F, Magagnoli M, Albertini P, Tura S: Clinical implications of serum levels of soluble CD30 in 70 adult anaplastic large-cell lymphoma patients. J Clin Oncol 1998;16:1532–1537.
  6. Nadali G, Tavecchia L, Zanolin E, Bonfante V, Viviani S, Camerini E, Musto P, Di Renzo N, Carotenuto M, Chilosi M, Krampera M, Pizzolo G: Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin’s disease at high risk of unfavorable outcome. Blood 1998;91:3011–3016.
  7. Zanotti R, Trolese A, Ambrosetti A, Nadali G, Visco C, Ricetti MM, Benedetti F, Pizzolo G: Serum levels of soluble CD30 improve International Prognostic Score in predicting the outcome of advanced Hodgkin’s lymphoma. Ann Oncol 2002;13:1908–1914.
  8. Knowles DM: Etiology and pathogenesis of AIDS-related non-Hodgkin’s lymphoma. Hematol Oncol Clin North Am 2003;17:785–820.
  9. Martínez-Maza O, Widney D, van der Meijden M, Knox R, Echeverri A, Breen EC, Magpantay L, Miles S: Immune dysfunction and the pathogenesis of AIDS-associated non-Hodgkin’s lymphoma. Mem Inst Oswaldo Cruz 1998;93:373–381.
  10. Detels R, Phair JP, Saah AJ, Rinaldo CR Jr, Muñoz A, Kaslow RA, Seminara D, Schrager L, Vermund S: Recent scientific contributions to understanding HIV/AIDS from the Multicenter AIDS Cohort Study. J Epidemiol 1992;2(suppl):S11–S19.
  11. Centers for Disease Control: 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992;41:1–19.
  12. Yawetz S, Cumberland WG, van der Meyden M, Martínez-Maza O: Elevated serum levels of soluble CD23 (sCD23) precede the appearance of acquired immunodeficiency syndrome-associated non-Hodgkin’s lymphoma. Blood 1995;85:1843–1849.
  13. Breen EC, van der Meijden M, Cumberland W, Kishimoto T, Detels R, Martínez-Maza O: The development of AIDS-associated Burkitt’s/small noncleaved cell lymphoma is preceded by elevated serum levels of interleukin 6. Clin Immunol 1999;92:293–299.
  14. Widney D, Gundapp G, Said JW, van der Meijden M, Bonavida B, Demidem A, Trevisan C, Taylor J, Detels R, Martínez-Maza O: Aberrant expression of CD27 and soluble CD27 (sCD27) in HIV infection and in AIDS-associated lymphoma. Clin Immunol 1999;93:114–123.
  15. Schroeder J, Saah AJ, Hoover DR, Margolick JB, Ambinder RF, Martínez-Maza O, Crabb Breen E, Jacobson LP, Variakojis D, Rowe DT, Armenian HK: Serum soluble CD23 level correlates with subsequent development of AIDS-related non-Hodgkin’s lymphoma. Cancer Epidemiol Biomarkers Prev 1999;8:979–984.
  16. Breen EC, Boscardin WJ, Detels R, Jacobson L, Smith MW, O’Brien SJ, Chmiel JS, Rinaldo CR, Lai S, Martínez-Maza O: Non-Hodgkin’s B cell lymphoma in persons with acquired immunodeficiency syndrome is associated with increased serum levels of IL10, or the IL10 promoter -592 C/C genotype. Clin Immunol 2003;109:119–129.
  17. Breen EC, Epeldegui M, Boscardin WJ, Widney DP, Detels R, Martínez-Maza O: Elevated levels of soluble CD44 (sCD44) precede the development of AIDS-associated NHL. AIDS 2005;19:1711–1712.
  18. Widney DP, Breen EC, Boscardin WJ, Smith JB, Detels R, Martínez-Maza O: Serum levels of the homeostatic B cell chemokine, CXCL13, are elevated during HIV infection. J Interferon Cytokine Res, in press.
  19. Lane HC, Fauci AS: Immunologic abnormalities in the acquired immunodeficiency syndrome. Annu Rev Immunol 1985;3:477–500.
  20. Pizzolo G, Vinante F, Morosato L, Nadali G, Chilosi M, Gandini G, Sinicco A, Raiteri R, Semenzato G, Stein H, Perona G: High serum level of the soluble form of CD30 molecule in the early phase of HIV-1 infection as an independent predictor of the progression to AIDS. AIDS 1994;8:741–745.
  21. Sabin CA, Bofill M, Phillips AN, Elford J, Janossy G, Lee CA: Relation between soluble CD30 levels measured soon after HIV seroconversion and disease progression in men with hemophilia. J Acquir Immune Defic Syndr Hum Retrovirol 1997;16:279–283.
  22. Rizzardi GP, Tambussi G, Barcellini W, Capiluppi B, Clerici E, La Maestra L, Lillo F, Pantaleo G, Lazzarin A: Soluble CD30, tumour necrosis factor (TNF)-α, and TNF receptors in primary HIV-1 infection: relationship with HIV-1 RNA, clinical outcome and early antiviral therapy. J Biol Regul Homeost Agents 1997;11:43–49.
  23. Schroeder J, Saah A, Ambinder RF, Martínez-Maza O, Crabb Breen E, Variakojis D, Margolick JB, Jacobson LP, Rowe DT, Hoover DR: Serum sCD23 level in patients with AIDS-related non-Hodgkin’s lymphoma is associated with the absence of EBV in tumor tissue. Clin Immunol 1999;93:239–244.
  24. Keane NM, Price P, Lee S, Stone SF, French MA: An evaluation of serum soluble CD30 levels and serum CD26 (DPPIV) enzyme activity as markers of type 2 and type 1 cytokines in HIV patients receiving highly active antiretroviral therapy. Clin Exp Immunol 2001;126:111–116.
  25. Romagnani S, Del Prete G, Maggi E, Chilosi M, Caligaris-Cappio F, Pizzolo G: CD30 and type 2 T helper (Th2) responses. J Leukoc Biol 1995;57:726–730.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50